BROAD.MIT.EDU : www.broad.mit.edu - 164 in TOP 100 MEDICAL SITES. Rating: 27200.

Description: The Eli and Edythe L. Broad Institute: A collaboration of Massachusetts Institute of Technology, Harvard University and affiliated Hospitals, and Whitehead Institute for Biomedical Research

Most popular searches: www.brad.mit.edu, www.broad.mite.du, Harvard University, www.boad.mit.edu, www.broad.imt.edu, chimpanzee genome, www.broad.mt.edu, dog genome, Eli Broad, ww.broad.mit.edu, wwwbroad.mit.edu, www.broadmit.edu, Eric S. Lander, www.broa.mit.edu, www.rboad.mit.edu, www.brod.mit.edu, wwwb.road.mit.edu, www.broad.mit.du, Cambridge, www.broad.mit.eu, www.road.mit.edu, www.broad.mit.deu, www.broa.dmit.edu, affiliated Hospitals, MIT, Chad Nusbaum, Stuart Schreiber, www.broad.mti.edu, www.braod.mit.edu, genom, www.broad.it.edu, mouse genome, Bruce Birren, Eli and Edythe L. Broad Institute, www.broad.mi.edu, www.broad.mit.edu, Kerstin Lindblad-Toh, www.broad.mitedu, www.broda.mit.edu, Massachusetts, Whitehead Institute for Biomedical Research, David Altshuler, ww.broad.mit.edu, ww.wbroad.mit.edu, www.broad.mit.edu, www.broad.mit.com, Jill Mesirov, Todd Golub, human genome project, wwwbroad.mit.edu, www.broad.mit.eud, www.broadm.it.edu, www.broad.mi.tedu, www.broad.mit.ed, www.borad.mit.edu, Broad Institute of MIT and Harvard

PPD Raises Annual Dividend Rate (AP)
Pharmaceutical Product Development Inc., a provider of contract drug-development research, said Tuesday it raised its annual cash dividend rate to 40 cents from 12 cents.
us.rd.yahoo.com

Mountain View birth-control company gets competition wish
The CEO of Conceptus Inc. says he used to wish for a little competition, figuring it might create a little buzz.
feeds.bizjournals.com

Northeastern University working on breast cancer screening technology
Northeastern University is working with Massachusetts General Hospital on developing new technology to improve the accuracy of breast cancer screening.
feeds.bizjournals.com

Validity of Takeda's Prevacid Patents Upheld; Teva's Obviousness Arguments Rejected
Aaron F. Barkoff submits: Following a week-long bench trial held last year, the U.S. District Court for the District of Delaware released an opinion (pdf file) on March 31 stating that Takeda's (TKPHF.PK) patents on Prevacid (lansoprazole) are valid and that Teva's (TEVA) ANDA for a generic version of Prevacid capsules infringes one of the patents. Prevacid, a treatment for acid reflux, heartburn and stomach ulcers, had $3.4 billion in U.S. sales last year.Takeda asserted U.S. Patent Nos. 4,628,098, covering the lansoprazole compound, and 5,045,321, covering a pharmaceutical composition of lansoprazole, against Teva. Teva conceded that its generic drug product infringes the '098 patent, though it contested infringement of the '321 patent. Moreover, Teva argued that the '098 and '321 patents are invalid for obviousness and unenforceable due to inequitable conduct.Complete Story »
seekingalpha.com

SAC Discloses 5.1% Stake in ABI: Wants Celera Separated, CEO Gone, and All Options Explored
Lon Juricic submits: In a 13D filing after the close Friday on Applied Biosystems (ABI),Steven Cohen's SAC Capital disclosed a 5.1% stake (8,604,018 shares) inthe company. SAC showed a 222,357 share stake at the quarter ended12/31/07.In the filing, SAC disclosed that in March 2008 itsent a letter to the company's non-management directors expressing itscontinued support for the separation of the company's Celera Group. Complete Story »
seekingalpha.com